Bringing together global experts in a new series of senior leadership, virtual panel discussions on precision oncology and precision medicine.

Just 60 mins – a bitesize chunk, easy to fit into your diary.


Welcome to Our New Virtual Panel Series

COVID-19 has had an immeasurable impact upon the way we communicate and share ideas with little or no human interaction at live in-person conferences. If we have learned one thing from the pandemic it is the fact that collaboration is critical – what we have been saying for years about precision medicine if it is to become a ubiquitous reality. Our virtual panel sessions provide a platform to hear from the leaders in the field in an open, interactive format, rather than just through PowerPoint presentations. This format, along with ample time for discussion, we find provides a more collaborative approach than just watching a slide-deck remotely.

Precision Medicine Forum and Precision Oncology Forum - Virtual Panel Series aims to educate and offer perspectives to the clinicians, researchers, industry and patient groups and those within their respective institutions who are tasked with building the necessary systems and solutions to harness the full potential of precision medicine.

We convene a group of experts from a range of disciplines within precision medicine, and via a moderated discussion, allow unique insights in a relaxed, interactive environment. Our platform allows for audience Q&A, polls, and open discussion amongst the panellists to create a fully immersive experience. Our attendee research confirms that it is difficult to retain interest while sat at a laptop for hours on end, so our bi-weekly 60 min. sessions help to make each session more interactive, with greater flexibility to fit into attendees’ busy schedules and ensure increased attendee retention for the full session.

With so many different healthcare systems and research techniques available to us globally, we feel it is important to ensure we are reaching an audience during their working day. As such, for each of the topics we have a 60 min. session in the European time zone (with European speakers), followed later in the day in the US time zone with US speakers.

  • 4-6 panellists
  • 60 min sessions
  • Candid conversation amongst KOLs
  • Free to attend
  • Live and on-demand
  • Thought leadership, NOT sales pitches

October 22, 2020

The Impact of COVID-19 on Cancer Treatment and Screening

  • Quantifying the impact of COVID-19 on cancer screening, tests, and treatments
  • Creating a safe environment for cancer patients as we emerge from lock-down: 
    • rebuilding trust and encouraging people to seek help
    • managing treatment for international patients
  • Ramping up screening and effectively clearing the backlog
  • Developing a strategy to increase hospital testing capacity, increase turn-around times, and prioritise effectively  
  • Assessing the collateral damage to cancer patients due to global pandemics
  • What lessons have we learned and how can these be applied to future localised restrictions and pandemics?


Sara Badreh, Senior Manager Health and Research Projects, European Cancer Patient Coalition

10.00 BST


  • Dr Antonio Calles, Medical Oncologist, Hospital General Universitario Gregorio Marañón
  • Dorothy Erlanger, Chair of the Patient Advocate Committee, National Cancer Institute
  • Prof Justin Stebbing, Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust

16.00 BST


  • Dorothy Erlanger, Chair of the Patient Advocate Committee, National Cancer Institute
  • Dr Len Lichtenfeld, (Former) Deputy Chief Medical Officer, American Cancer Society
  • Dr Maurie Markman, President, Medicine and Science, Cancer Treatment Centers of America

November 5, 2020

Moving Beyond Genomics – The Development of Functional or Systems Precision Medicine

Genomic profiling is driving the development of precision medicine, particularly with regards to oncology. However, a key challenge is being able to match effective drugs to genomic profiles, which are often complex and unique to each patient. Furthermore, even when it is possible to target certain genes, it is not always clear which one should be prioritised, or which drug would be most effective. 

This session will explore how the development and application of functional analysis could be used as a precision medicine tool alongside genomic-focused approaches to improve targeted drug development and accelerate clinical implementation. 

10.00 GMT


Prof Dr Walter Kolch,  Director Systems Biology Ireland, School of Medicine , University College Dublin


  • Dr Päivi Östling, Associate Professor & Co-Principal Investigator, Kallioniemi Research Group, SciLifeLab
  • Dr Sigrid Skånland, Lab Leader & Researcher, Institute of Cancer Research, Oslo University Hospital
  • Prof Dr Krister Wennerberg, Biotech Research & Innovation Centre (BRIC), University of Copenhagen

November 12, 2020

Molecular Tumour Boards and Virtual Molecular Tumour Boards to Enable Individual Personalised Treatment Decisions

The clinical and molecular heterogeneity of tumours and their evolution after diagnosis and treatment presents major challenges to effective cancer therapy. Understanding what 'steps' a cell must take to become cancerous, as well as the influence of external factors such as inherited genetic factors, metabolic profiles, and lifestyle factors, and being able to unravel the mechanisms of drug resistance are all fundamental to the development of precision oncology strategies. 

Molecular Tumour Boards play an increasingly critical role in cancer diagnosis and treatment and advances in these, including the development of virtual molecular tumour boards (vMTB), will further enable the development of new solutions in oncology clinical practice. 

10.00 GMT


Dr C. Benedikt Westphalen, Head, Molecular Diagnostics and Therapy Program and the Molecular Tumor Board, CCC München – Comprehensive Cancer Center


  • Dr Maud Kamal, Scientific Manager, Department of Drug Development and Innovation (D3i), Institut Curie
  • Prof Dr Janne Lehtiö, Professor, Karolinska Institutet, Scientific Director, Science for Life Laboratory & Board of Directors, Karolinska Comprehensive Cancer Center
  • Dr Julien Masliah Planchon, Molecular Biologist, Institut Curie
  • Dr David Tamborero, Researcher, Dept of Oncology-Pathology, Karolinska Institutet

December 3, 2020

The Impact of COVID-19 on Clinical Trials in Oncology

  • Quantifying the impact of COVID-19 on clinical trials and treatment pipelines 
  • Keeping patient safety at the forefront to enable trials to restart
    • prioritising which trials should be restarted first
  • Detailing the impact of funding pressures on clinical trial programmes and what support is available  
  • Are there positive lessons to be learnt? Evaluating the use of remote data collection, video consultation and home treatments and their potential future use

10.00 GMT


  • Dr Donna Graham, Consultant in Experimental Cancer Medicine & Hon. Clinical Lecturer, The Christie NHS Foundation Trust & University of Manchester


  • Dr Capucine Baldini, Medical Oncologist, Drug Development (DITEP), Institut de Cancérologie Gustave Roussy
  • Prof Robert Jones MBChB PhD, Head, Cancer Clinical Trials Unit, Scotland, & Cancer Research UK Glasgow Clinical Trials Unit
  • Eibhlín Mulroe, Chief Executive, Cancer Trials Ireland

December 17, 2020

Immuno-Oncology: Exploring Advances in Developing Cancer Immunotherapies

There are huge expectations for cancer immunotherapies and their potential to manipulate the patient’s own immune system in order to fight tumour cells and treat the disease. Whilst much progress has been made in this area, there have also been set-backs and the price, hope and hype associated with cancer immunotherapy places a lot of pressure on clinicians. This session will explore new approaches for optimising response and minimising resistance to cancer immunotherapies. 

  • Assessing the type of cancer to which immunotherapy will be most beneficial and implementing it in a personalised approach:
    • developing different therapies for different patients and cancers
    • determining likely timescales for regulatory guidance for actively personalised immunotherapies
  • Exploring the evolution and development of CAR-T cells for effective immunotherapy and precision oncology: 
    • identifying novel targets for CAR-T cells
    • Increasing their effectiveness for solid tumours
  • Examining the potential of neoantigens for cancer immunotherapy

11.30 GMT


  • Prof Dr Mark Lawler, Associate Pro-Vice-Chancellor & Professor of Digital Health, Faculty of Medicine, Health and Life Sciences & Chair in Translational Cancer Genomics, Queen's University Belfast & Scientific Committee Member, European Cancer Patient Coalition


  • Prof Ann Ager, Professor of Cellular Immunity and Immunotherapy and Theme Lead for Inflammation, Division of Infection and Immunity, Cardiff University
  • Prof Magnus Essand, Professor, Clinical Immunology, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University
  • Prof Dr Kjetil Taskén, Head & Director, Institute for Cancer Research - Norwegian Radium Hospital and Group Leader, Dept of Cancer Immunology, Oslo University Hospital. Professor, Institute of Clinical Medicine, University of Oslo

January 13, 2021

Managing the Legal, Regulatory & Ethical Implications of Sharing and Using Data

(Patient, Biological & Healthcare Data)

  • Determining the extent to which current GDPR and other data regulations are sufficient to cover the use of patient data: 
    • how does specific provision for scientific research within General Data Protection Regulation (GDPR) differ across European countries
    • what frameworks, principles and norms have so far been developed to ensure an ethical approach to data sharing in health research?
    • what additional data governance requirements might be needed?
  • Addressing ethical concerns with regards to patient privacy and confidentiality and ensuring any potential risks are transparent to all concerned - to what extent is anonymisation whilst allowing effective use of patient data achievable?
  • Managing the balance between patient privacy rights and the benefits of data-sharing
    • understanding patients’ expectations of research and the societal benefits and value from it 
    • how do we generate and maintain patient trust with regards to their personal information?
  • Exploring the current and potential uses of AI and digital technologies for healthcare data and the implications of this:
    • legal and regulatory compliance
    • patient trust & engagement

10.00 GMT


  • Dr Deborah Mascalzoni, Research Group Leader, Institute for Biomedicine, EURAC; Senior Researcher, Centre for Research Ethics & Bioethics, Uppsala University & Centre for Health, Law & Emerging Technologies (HELEX), University of Oxford


  • Prof Dr Ana Nordberg, Associate Senior Lecturer, Faculty of Law, Lund University
  • Dr Marjut Salokannel docent, Founding Partner, Salokannel Research & Consulting SaReCo Oy
  • Dr Mahsa Shabani, Assistant Professor in Privacy Law, Ghent University

February 4, 2021

Innovative Clinical Trial Design for Precision Oncology

New approaches to clinical trials have the potential to accelerate research and drug development so that the right therapies can rapidly be delivered to the right patients. However, there are a number of issues affecting progress such as regulatory and reimbursement constraints due to the cost and complexity of clinical trial design. This session will explore key issues including:

  • The latest thinking in clinical trial design: platform, umbrella, basket, histology-agnostic and incorporating AI into trial design:
    •  how has COVID-19 changed the way we design, register and conduct clinical trials?
  • Exploring what changes need to be made to current trial design to better enable a precision approach
  • Integrating real-world data with other information sources to select the “right” patients
  • What do payers need to see in order to fund and support access to targeted therapy? 
  • Enabling patient empowerment in the clinical trial and drug development process

16.00 GMT


  • Dr Razelle Kurzrock, Distinguished Professor of Medicine, University of California San Diego School of Medicine, Director, Center for Personalized Cancer Therapy and Rare Tumor Clinic, Associate Director, Clinical Science Leader, Experimental Therapeutics, UCSD Moores Cancer Center


  • Penilla Gunther, Project Leader, FOKUS Patient
  • Prof Dr Åslaug Helland, Group Leader, Institute for Cancer Research & Senior Oncologist, Dept of Oncology, Norwegian Radium Hospital (NRH) and Oslo University Hospital

February 11, 2021

The Impact of COVID-19 on Cancer Research

  • Keeping labs up and running and protecting the need for medical research and clinical trials going forward
  • Exploring ways to fill the funding gap from lost donations and fundraising:
    • identifying new funding and research project financing opportunities 
  • Examining Government support available and how this can best enable and support a thriving research environment 
    • how can funders and institutions support scientists and ensure the healthy future of research?
    • the role of technology in supporting and accelerating research

10.00 GMT


  • Dr John Rowell, Chief Scientific Officer, Grants, Gustave Roussy


  • Prof Dr Ingemar Ernberg, Professor, Department of Microbiology, Tumour and Cell Biology & Chair, Personalised Cancer Medicine (PCM) Programme, Karolinska Institutet
  • Zoe Martin, Policy Manager, Cancer Research UK
  • Dr Sheuli Porkess, Interim Medical Director, The Association of the British Pharmaceutical Industry (ABPI)

February 25, 2021

Examining How Healthcare Systems Need to Adapt in Order to Truly Deliver Precision Medicine

  • Assessing the infrastructure, data and technology changes required to current healthcare systems in order to deliver a precision medicine approach
  • Research / Clinic interaction: Exploring how to translate broad genomic and multi-omic profiling data into actionable insights that can be used in clinics
  • Discovering innovative ways of reorganising healthcare systems with limited resources
  • Developing and implementing precision medicine communication & training programmes for healthcare professionals (HCPs)

10.00 GMT


  • Prof Dr Dhavendra Kumar, Honorary Clinical Professor, William Harvey Research Institute, Bart's and the London School of Medicine & Dentistry, Queen Mary University of London & CEO / Medical Director, The Genomic Medicine Foundation UK
  • Helen Lepa, Consultant, Personalized Medicine, Estonian National Institute for Health Development
  • Dr Sowmiya Moorthie, Senior Policy Analyst, PHG Foundation
  • Dr Astrid Moura Vicente, Principal Investigator and Head of the Department of Health Promotion & Non-Communicable Disease Prevention, The National Health Institute Doutor Ricardo Jorge (INSA)